



Article Mitochondrial DNA Copy Number Is Associated with the Severity of Irritable Bowel Syndrome

Soo-Jung Jung ^{1,2,†}, Jae-Ho Lee ^{3,†}, Ji-Yeon Lim ⁴ and Yun-Yi Yang ^{5,*}

- ¹ Department of Physiology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea; soojung4234@knu.ac.kr
- ² Cell and Matrix Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea
- ³ Department of Anatomy, School of Medicine, Keimyung University, 1095 Dalgubeol-daero, Daegu 42601, Republic of Korea; anato82@dsmc.or.kr
- ⁴ Department of Food Science and Nutrition, Keimyung University, 1095 Dalgubeol-daero, Daegu 42601, Republic of Korea; ynyn2121@naver.com
- ⁵ Department of Nursing, Healthcare Science & Human Ecology, Dong-Eui University, Busan 47340, Republic of Korea
- * Correspondence: yangyunyi@deu.ac.kr; Tel.: +82-51-890-4253
- ⁺ These authors contributed equally to this work.

Abstract: *Background and Objectives*: Irritable bowel syndrome (IBS), as a gastrointestinal disorder, presents with abdomen pain and alterations in the bowel habits. Its pathogenesis remains unclear. Here, we examined mitochondrial DNA copy number (mtCN) in IBS and its clinical value. *Materials and Methods*: mtCN was analyzed in 43 IBS patients using quantitative real-time polymerase chain reaction. Furthermore, data on the clinical characteristics of patients and symptom severity of IBS were collected, and their association with mtCN was analyzed. *Results*: mtCN was higher in patients with IBS (p = 0.008) and those with a drinking habit (p = 0.004). Smoking and the presence of a sleep partner showed a possible association with mtCN; however, it did not reach significance. The severity of IBS symptoms tended to positively correlate with mtCN (r = 0.279, p = 0.070). *Conclusions*: Overall, we demonstrated a potential association between mtCN and the clinicopathologic characteristics of patients with IBS. Further studies considering genetic and clinical factors are required.

Keywords: irritable bowel syndrome; mitochondrial DNA copy number; mitochondria; mitochondria content

1. Introduction

Irritable bowel syndrome (IBS) is a common disorder in the gastrointestinal tract, characterized by chronic abdominal pain with constipation, diarrhea, and an altered bowel pattern alternating between constipation and diarrhea, characterized by bloating, incomplete bowel movements, and discomfort [1]. IBS affects approximately 11% of the world population, and 55% of patients are women [2,3]. Its prevalence is 10–25% in the United States, 17–21% in South America, 7–9% in South Asia, and 5.6% in the Middle East and Africa [2–4]. In particular, the prevalence rate of IBS among college students in their 20s is higher than that in other age groups [5]. According to a recent study, IBS imposes a social, economic, and psychological burden and is also associated with a low quality of life; the diagnosis and the treatment of IBS are difficult because it affects the visceral–brain axis, which is associated with mental health symptoms such as anxiety and depression [6].

Mitochondria generate approximately 90% of adenosine triphosphate (ATP) for cellular energy through the process of oxidative phosphorylation (OXPHOS) in cells. Mitochondria have their own DNA (mtDNA), which encodes many proteins important for assembly and activity, and each mitochondrion contains multiple copies of mtDNA [7]. The total content of mtDNA in cells is regulated according to metabolic requirements [8]. Therefore, mtDNA content is tissue- and developmental-stage-specific and finely regulated



Citation: Jung, S.-J.; Lee, J.-H.; Lim, J.-Y.; Yang, Y.-Y. Mitochondrial DNA Copy Number Is Associated with the Severity of Irritable Bowel Syndrome. *Medicina* **2024**, *60*, 1605. https://doi.org/10.3390/ medicina60101605

Academic Editor: Jan Bilski

Received: 23 August 2024 Revised: 19 September 2024 Accepted: 27 September 2024 Published: 1 October 2024



Copyright: © 2024 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/ licenses/by/4.0/). by a balance between replication and turnover. Previous studies using human tissues demonstrated that mtDNA copy number (mtCN) per cell may vary by several orders of magnitude: $\sim 1 \times 10^5$ mtDNA copies in oocytes [9]; $\sim 4-6 \times 10^3$ in the heart; $0.5-2 \times 10^3$ in the lungs, liver, and kidney [10]. Although mtDNA plays an essential role in regulating apoptosis and metabolism, it has a high mutation rate [11]. Pathogenic mutations have been documented in mitochondrial tRNA, rRNA, and protein-coding genes, and they invariably compromise mitochondrial gene expression, causing various degrees of OXPHOS deficiency. Mutations occur more frequently in mtDNA than in nuclear DNA (nDNA) because of the insufficient repair systems in the mitochondria, which can lead to various diseases [12]. mtCN in a cell can vary widely by organism, tissue, and cell type. Furthermore, differences in mtCN may be associated with many diseases, especially gastric and colon cancers, and genetic changes are associated with colorectal carcinogenesis [12–14].

A previous study has demonstrated that mtDNA levels are reduced in aging and neurodegenerative disorders, like Alzheimer's disease, Parkinson's disease, etc. [15]. However, the results differed according to the quality and composition of the specimens. It is not clear how the disruption of the mtCN is related to IBS. To better understand this relationship, we aimed to determine the clinical characteristics of patients with IBS and mtCN and discuss the clinical significance of mtCN in this study. As mtCN may vary depending on age and genetic status, this study was performed in college students without hereditary disorders.

2. Materials and Methods

2.1. Participants

Participants who met the inclusion criteria were recruited by advertisements on the bulletin boards in Daegu, South Korea. The inclusion criteria were as follows: (1) college students over 18 years old; (2) meeting the Rome III Diagnostic Criteria for IBS [1]; (3) no previous history of surgeries and diagnosed disorders in the gastrointestinal tract such as obstructive bowel disorders, inflammatory bowel disorders, and lactose malabsorption; (4) no previous history of psychiatric diseases. A total of 43 participants with IBS were contacted.

The severity of IBS symptoms was measured using previous published criteria [16]. These consist of seven items, and after excluding the categorical questions inquiring about the presence of abdominal pain or abdominal bloating, the remaining five questions were scored 100 points each using the visual analog scale (VAS): Q1 = abdominal pain, Q2 = bloating and flatulence, Q3 = bowel habits (diarrhea and constipation), Q4 = perception of psychological wellbeing, and Q5 = daily life influenced by GI problem. The severity was determined by the sum of the above five scales and was classified as follows: 75–174 = mild, 175–299 = moderate, and 300–500 = severe. Our previous study showed that the reproducibility of this scale at the time of development was stable (85%), and Cronbach's α level indicating reliability was 0.72 [5].

2.2. DNA Extraction

Blood, to obtain serum, was collected from 43 participants. Informed consent was verbally obtained from all participants and/or their legal guardian. The Institutional Review Board of the Keimyung University Dongsan Medical Center approved the protocols necessary for the research. Genomic DNA was extracted from serum using a DNA extraction kit (Qiagen, Inc., Valencia, CA, USA). Its quantity and quality were measured using NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA).

2.3. Mitochondrial DNA Copy Number

The mtCN was investigated using a real-time quantitative polymerase chain reaction (qPCR) assay. For the quantitative determination of the mtDNA, its contents relative to the nDNA contents were analyzed. Based on a previous study [15], specific primers for the amplification of mitochondrial COX1 and nuclear β -actin were selected. qPCR was performed using the LightCycler 480 II system (Roche Diagnostics, Mannheim, Germany),

with a reaction mixture with a total volume of 20 μ L, containing 50 ng of DNA, 8 pmol of each primer, and 10 μ L of SYBR Green Master MIX (Takara, Kyoto, Japan). The PCR conditions were as follows: 95 °C for 40 s, followed by 40 cycles at 95 °C for 20 s and 60 °C for 30 s.

The threshold cycle number (Ct) values of mitochondrial COXI and β -actin were determined. The level of mtCN in each specimen was normalized against β -actin level in the same participants. All measurements were repeated three times, and five serial dilutions were performed for the control samples.

2.4. Statistical Analysis

All statistical analyses were performed using the SPSS statistical package, version 25.0, for Windows. The chi-square test was used to analyze the associations between the variables. A two-tailed p value of less than 0.05 was considered to indicate statistical significance.

3. Results

In the present study, mtCN was successfully analyzed in all 43 participants. The average mtCN was 0.57 ± 0.3 , and the participants were divided into high and low groups according to the median value of mtCN. The clinical characteristics of patients with IBS and mtCN were investigated, and the results are summarized in Table 1. IBS was divided into the following subtypes: diarrhea-predominant, constipation-predominant, and mixed types. Both diarrhea and constipation types tended to be associated with a lower mtCN; however, the association was not significant. mtCN was significantly higher in male participants (p = 0.008) and those with a drinking habit (p = 0.004). Smoking and the presence of a sleep partner tended to have an association with a higher mtCN but this association did not reach significance (p = 0.052). Other clinical characteristics did not have any relationship with mtCN.

		mtCN (N, %)			
	-	Low	High	р	
	D-predominant	2 (66.7)	1 (33.3)	0.390	
Subtype	C-predominant	2 (100)	0 (0)		
	Mixed	20 (52.6)	18 (47.4)		
C	Male	0 (0)	5 (100)	0.008	
Sex	Female	24 (63.2)	14 (36.8)		
Crea altima	No	22 (62.9)	13 (37.1)	0.052	
Smoking	Yes	2 (25.0)	6 (75.0)		
Duinlin	No	18 (75.0)	6 (25.0)	0.004	
Drinking	Yes	6 (31.6)	13 (68.4)		
<u>Classical</u>	No	20 (64.5)	11 (35.5)	0.065	
Sleep partner	Yes	4 (33.3)	8 (66.7)		
Ni ah tala ta	No	16 (53.3)	14 (46.7)	0.619	
Night duty	Yes	8 (61.5)	5 (38.5)		
	No	24 (57.1)	18 (42.9)	0.255	
Cardiovascular disease	Yes	0 (0)	1 (100)		
	No	17 (53.1)	15 (46.9)	0.545	
Inflammatory bowel disease	Yes	7 (63.6)	4 (36.4)		
	No	23 (54.8)	19 (45.2)) 0.368	
Sleep apnea	Yes	1 (100)	0 (0)		
	No	16 (51.6)	15 (48.4)	0.070	
Anxietas tibiarum	Yes	8 (66.7)	4 (33.3)	0.373	
	Mild	0 (0)	1 (100)		
Visual analog scale	Moderate	7 (53.8)	6 (46.2)	0.503	
-	Severe	17 (58.6)	12 (41.4)		

 Table 1. Clinical significance of mitochondrial DNA copy number (mtCN) in IBS.

D-predominant, diarrhea-predominant; C-predominant, constipation-predominant.

The severity score for IBS symptoms was 319.42 ± 64.84 in this study. Correlation analysis showed that the severity of IBS tended to positively correlate with mtCN (r = 0.279, p = 0.070), but the correlation was not significant.

The correlation between VAS scales and mtCN was analyzed, and the results are presented in Table 2. mtCN varied from 0 to about 8, and VAS scales were scored 100 points each. As a result, mtCN showed no significant association with any of the VAS scales. Age negatively correlated with abdominal pain (Q1) (r = -0.329, p = 0.031, Figure 1). Abdominal pain was also associated with bloating (Q2) (r = 0.506, p = 0.001) and VAS sum (r = 0.380, p = 0.012).




Figure 1. Positive correlation between the severity of IBS symptoms and mtCN.

		mtCN	Age	Q1	Q2	Q3	Q4	Q5	Sum
mtCN	r	1	-0.048	0.104	0.232	0.242	0.143	0.030	0.279
	р		0.758	0.507	0.135	0.118	0.361	0.847	0.070
Age	R		1	-0.329	-0.132	0.086	0.114	0.270	0.015
	Р			0.031	0.398	0.583	0.466	0.080	0.924
Q1	R			1	0.506	-0.070	-0.067	-0.023	0.380
	Р				0.001	0.657	0.671	0.883	0.012
Q2	R				1	-0.061	-0.008	0.063	0.521
	Р					0.699	0.961	0.686	0.000
Q3	R					1	0.655	0.407	0.709
	Р						0.000	0.007	0.000
Q4	R						1	0.286	0.716
	Р							0.063	0.000
Q5	R							1	0.535
	Р								0.000

Table 2. Correlation between VAS scales and mitochondrial DNA copy number (mtCN).

 $\overline{Q1}$ = abdominal pain; Q2 = bloating and flatulence; Q3 = bowel habits (diarrhea and constipation); Q4 = perception of psychological wellbeing; Q5 = daily-life-related GI problem.

4. Discussion

In this study, we confirmed the relationship between mtCN and clinical features of IBS for the first time. As mitochondrial function in IBS is unclear, we studied the relationship between the clinical characteristics of patients with IBS and mtCN. Our study showed that many clinical characteristics are associated with mtCN in IBS. Interestingly, male patients with IBS and patients with a drinking habit had a significantly higher mtCN. Elevated mtCN is considered a marker for oxidative stress and was found to be present in various cancers, though this is still controversial [12–14,17]. Smoking and the presence of a sleep

partner correlated with a higher mtCN. These factors may influence the quality of sleep [18]. In unmarried college students, the presence of a sleep partner could have various effects on sleep [5]. If your lifestyle and sleeping habits do not match those of your partner, sleep quality deteriorates, causing problems with the rhythm of life and difficulties with bowel habits. A previous study has demonstrated that heavy and frequent smoking and alcohol use are associated with both insomnia symptoms and sleep dissatisfaction [16]. The underlying mechanism of the comorbidity of IBS and insomnia is unclear; the gut-brain axis may have an important role in their relation [19]. A previous study suggested that sleep disorders may occur due to simple digestive disorders such as indigestion [20]. This could cause an imbalance between the autonomic nervous system (ANS) and the hypothalamicpituitary-adrenal axis, increasing hypersensitivity to visceral pain [20-22]. Mitochondrial damage can lead to ATP depletion and excessive Ca²⁺ concentrations, increasing mitochondrial membrane permeability. This enables the accumulation of ROS, contributing to the pathogenesis of a variety of neurological conditions [23]. Our results showed a potential correlation between mtCN and VAS score, including neuro-psychological symptoms, but the correlation was not significant. This finding supports the hypothesis that the mtCN– brain-gut axis may contribute to the development of IBS. However, the detailed molecular mechanism of this should be studied further using in vivo experiment models.

mtDNA is highly polymorphic and plays an essential role in apoptosis and metabolic regulation. As mtDNA lacks a repair system compared to nDNA, more mutations could occur in mtDNA than in nDNA. Recent studies have shown that single-nucleotide polymorphisms (SNPs) in mtDNA may be associated with the risk of IBS, especially diarrheapredominant IBS [24,25]. Alterations in mtDNA due to SNPs or other genetic disorders may aggravate IBS symptoms such as pain. Interestingly, regular exercise reduces cell-free mtDNA level and alleviates IBS symptoms [26]. Furthermore, mtDNA SNPs may predict the response to exercise and IBS prognosis in patients. Our results showed that mtCN was positively correlated to IBS severity. These findings suggest that mtCN reflecting mitochondrial DNA changes could be a biomarker for IBS severity or prognosis. However, the effect of mtCN differences and their function is unclear, and further studies should be carried out.

Caution should be exerted when interpretating our study findings. The number of participants in this study was insufficient, and there is a lack of data on IBS progression. A control group was absent in this study due to ethical reasons. Furthermore, information about this disease is scant, and not many patients regularly visit hospitals for treatment. In this respect, there is low relevance for our hypothesis regarding mtCN's function as a marker of IBS. Therefore, additional long-term follow-up studies should be conducted with a higher number of patients, including those with psychiatric diseases, such as bipolar disorder, schizophrenia, etc. The functional effect of mtCN was not demonstrated in this study, and its direct effect on IBS symptoms was also unclear. We also examined the correlation between mtCN and each VAS score; however, objective experimental studies of the severity of symptoms should be conducted.

5. Conclusions

The present study showed a relationship between the clinical characteristics of patients with IBS and mtCN. Sleep condition factors such as sex, drinking, and smoking, and the severity of IBS symptoms, were associated with mtCN, suggesting mtCN's potential as a biomarker of IBS. In order to develop a targeted treatment using mtCN for IBS, additional research on the mechanism of IBS pathogenesis is required. Although IBS is not classified as a major disease, continued research is required to improve patients' quality of life.

Author Contributions: Conceptualization, S.-J.J., J.-H.L. and Y.-Y.Y.; methodology, S.-J.J. and J.-H.L.; software, S.-J.J. and J.-Y.L.; validation, J.-H.L. and Y.-Y.Y.; formal analysis, S.-J.J. and J.-H.L.; writing—original draft preparation, S.-J.J. and J.-H.L.; writing—review and editing, all; visualization, S.-J.J. and J.-H.L.; supervision, Y.-Y.Y.; project administration, Y.-Y.Y.; funding acquisition, Y.-Y.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number) (NRF-2022R1I1A1A01068949 and RS-2024-00463771-0-1).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Keimyung University (40525-201809-BR-84-02, 18 October 2018).

Informed Consent Statement: Written informed consent was obtained from the patients or their guardians to publish this paper.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. Canavan, C.; West, J.; Card, T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014, 6, 71–80. [CrossRef] [PubMed]
- Liu, Y.; Liu, L.; Yang, Y.; He, Y.; Zhang, Y.; Wang, M.; Chen, S.; Yao, S. A school-based study of irritable bowel syndrome in medical students in Beijing, China: Prevalence and some related factors. *Gastroenterol. Res. Pract.* 2014, 124261. [CrossRef] [PubMed]
- Shiotani, A.; Miyanishi, T.; Takahashi, T. Sex differences in irritable bowel syndrome in Japanese university students. J. Gastroenterol. 2006, 41, 562–568. [CrossRef] [PubMed]
- 4. Cain, K.C.; Headstrom, P.; Jarrett, M.E.; Motzer, S.A.; Park, H.; Burr, R.L.; Surawicz, C.M.; Heitkemper, M.M. Abdominal pain impacts quality of life in women with irritable bowel syndrome. *Am. J. Gastroenterol.* **2006**, *101*, 124–132. [CrossRef]
- 5. Yang, Y.-Y.; Jun, S. Prevalence and associated factors of insomnia in college students with irritable bowel syndrome. *Korean J. Adult Nurs.* **2018**, *30*, 235–244. [CrossRef]
- 6. Ida, M.; Nishida, A.; Akiho, H.; Nakashima, Y.; Matsueda, K.; Fukudo, S. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. *Biopsychosoc. Med.* **2017**, *11*, 7. [CrossRef]
- 7. Howell, N.; Kubacka, I.; Mackey, D.A. How rapidly does the human mitochondrial genome evolve? *Am. J. Hum. Genet.* **1996**, *59*, 501–509.
- 8. Dickinson, A.; Yeung, K.Y.; Donoghue, J.; Baker, M.J.; Kelly, R.D.; McKenzie, M.; Johns, T.G.; St John, J.C. The regulation of mitochondrial DNA copy number in glioblastoma cells. *Cell Death Differ.* **2013**, *20*, 1644–1653. [CrossRef]
- 9. Chen, X.; Prosser, R.; Simonetti, S.; Sadlock, J.; Jagiello, G.; Schon, E.A. Rearranged mitochondrial genomes are present in human oocytes. *Am. J. Hum. Genet.* **1995**, *57*, 239–247.
- D'Erchia, A.M.; Atlante, A.; Gadaleta, G.; Pavesi, G.; Chiara, M.; De Virgilio, C.; Manzari, C.; Mastropasqua, F.; Prazzoli, G.M.; Picardi, E.; et al. Tissue-specific mtDNA abundance from exome data and its correlation with mitochondrial transcription, mass and respiratory activity. *Mitochondrion* 2015, 20, 13–21. [CrossRef]
- 11. Pääbo, S. Mutational hot spots in the mitochondrial microsome. Am. J. Hum. Genet. 1996, 59, 493–496. [PubMed]
- 12. Jung, S.J.; Cho, J.H.; Park, W.J.; Heo, Y.R.; Lee, J.H. Telomere length is correlated with mitochondrial DNA copy number in intestinal, but not diffuse, gastric cancer. *Oncol. Lett.* **2017**, *14*, 925–929. [CrossRef] [PubMed]
- 13. Lee, H.; Cho, J.H.; Park, W.J.; Jung, S.J.; Choi, I.J.; Lee, J.H. Loss of the association between telomere length and mitochondrial DNA copy number contribute to colorectal carcinogenesis. *Pathol. Oncol. Res.* **2018**, *24*, 323–328. [CrossRef] [PubMed]
- 14. Lee, J.H.; Hwang, I.; Kang, Y.N.; Choi, I.J.; Kim, D.K. Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis. *PLoS ONE* **2015**, *10*, e0118612. [CrossRef] [PubMed]
- 15. Filograna, R.; Mennuni, M.; Alsina, D.; Larsson, N.G. Mitochondrial DNA copy number in human disease: The more the better? *FEBS Lett.* **2021**, 595, 976–1002. [CrossRef]
- 16. Francis, C.Y.; Morris, J.; Whorwell, P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. *Aliment. Pharmacol. Ther.* **1997**, *11*, 395–402. [CrossRef]
- 17. Sun, X.; Zhan, L.; Chen, Y.; Wang, G.; He, L.; Wang, Q.; Zhou, F.; Yang, F.; Wu, J.; Wu, Y.; et al. Increased mtDNA copy number promotes cancer progression by enhancing mitochondrial oxidative phosphorylation in microsatellite-stable colorectal cancer. *Sig. Transduct. Target. Ther.* **2019**, *3*, 8. [CrossRef]
- Hussain, J.; Ling, L.; Alonzo, R.T.; Rodrigues, R.; Nicholson, K.; Stranges, S.; Anderson, K.K. Associations between sleep patterns, smoking, and alcohol use among older adults in Canada: Insights from the Canadian Longitudinal Study on Aging (CLSA). *Addict. Behav.* 2022, 132, 107345. [CrossRef]
- 19. Wang, B.; Duan, R.; Duan, L. Prevalence of sleep disorder in irritable bowel syndrome: A systematic review with meta-analysis. *Saudi J. Gastroenterol.* **2018**, *24*, 141–150. [CrossRef]
- 20. Miglis, M.G. Autonomic dysfunction in primary sleep disorders. *Sleep Med.* 2016, 19, 40–49. [CrossRef]
- Tobaldini, E.; Costantino, G.; Solbiati, M.; Cogliati, C.; Kara, T.; Nobili, L.; Montano, N. Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases. *Neurosci. Biobehav. Rev.* 2017, 74, 321–329. [CrossRef] [PubMed]
- 22. Vgontzas, A.N.; Chrousos, G.P. Sleep, the hypothalamic–pituitary–adrenal axis, and cytokines: Multiple interactions and dis-turbances in sleep disorders. *Endocrinol. Metab. Clin.* **2002**, *31*, 15–36. [CrossRef] [PubMed]

- 23. DiMauro, S.; Schon, E.A. Mitochondrial disorders in the nervous system. *Annu. Rev. Neurosci.* 2008, *31*, 91–123. [CrossRef] [PubMed]
- Camilleri, M.; Carlson, P.; Zinsmeister, A.R.; McKinzie, S.; Busciglio, I.; Burton, D.; Zaki, E.A.; Boles, R.G. Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2009, 296, G510–G516. [CrossRef]
- 25. Wang, W.F.; Li, X.; Guo, M.Z.; Chen, J.D.; Yang, Y.S.; Peng, L.H.; Wang, Y.H.; Zhang, C.Y.; Li, H.H. Mitochondrial ATP 6 and 8 polymorphisms in irritable bowel syndrome with diarrhea. *World J. Gastroenterol.* **2013**, *19*, 3847–3853. [CrossRef]
- 26. Chimienti, G.; Russo, F.; Bianco, A.; Maqoud, F.; De Virgilio, C.; Galeano, G.; Orlando, A.; Riezzo, G.; D'Attoma, B.; Ignazzi, A.; et al. Effect of a 12-week walking program monitored by Global Physical Capacity Score (GPCS) on circulating cell-free mtDNA and DNase activity in patients with irritable bowel syndrome. *Int. J. Mol. Sci.* 2024, 25, 4293. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.